Business Standard

Sun Pharma up 4% as US arm's Taro Pharma resolves antitrust investigation

Taro Pharma has reached a settlement agreement with the US Department of Justice, Antitrust and Civil divisions to pay more than $200 million to settle the generic drug price fixing allegations

Sun Pharma
Premium

Under a Deferred Prosecution Agreement reached with the DoJ, the Justice Department will file an Information for conduct that took place between 2013 and 2015

SI Reporter Mumbai
Shares of Sun Pharmaceutical Industries were up 4 per cent to Rs 496 in the early morning trade on the BSE on Friday after its US subsidiary, Taro Pharma reached a settlement agreement with the US Department of Justice (DoJ), Antitrust and Civil divisions to pay more than $200 million to settle the generic drug price fixing allegations against the company.

“Taro Pharmaceutical Industries has announced that its wholly-owned subsidiary, Taro Pharmaceuticals USA Inc., has resolved all cases involving the Company in connection with the multi-year investigations by the Department of Justice, Antitrust Division and Civil Division into the US generic

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 24 2020 | 9:49 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com